Ozempic competitor to launch in spite of PBS knockback

Eli Lilly’s Mounjaro will be on the private scrip market by the end of September Revolutionary new type 2 diabetes drug Mounjaro – which is almost better known for producing spectacular weight-loss results – will be launched in Australia later in September despite it not being added to the Pharmaceutical Benefits Scheme (PBS). The announcement

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Students fearful for future of pharmacy
Next Ramsay’s modest pharmacy operation a tiny chink of light